Azenosertib's accelerated approval path in Cyclin E1+ PROC hinges on DENALI Part 2 topline data expected year-end 2026

Bull

A positive readout would require a compelling and durable ORR in Cyclin E1+ PROC patients at the 400mg QD 5/2 dose, with a manageable safety profile and discontinuation rates meaningfully better than Part 1b — building on the differentiated signal already observed in the Part 2a interim analysis. Such a result would support an accelerated approval NDA submission, de-risk the ASPENOVA Phase 3 confirmatory trial, and validate the Cyclin E1 biomarker selection strategy, potentially positioning azenosertib as the first approved therapy specifically for this genomically defined PROC population.

Bear

The most likely failure modes are an ORR that falls short of an approvable threshold — either in magnitude or durability — insufficient to compel FDA to grant accelerated approval, or a safety profile driven by intolerable cumulative toxicity at 400mg that limits real-world applicability. A mixed signal, such as strong response in Part 2b but inconsistent data when Part 2a patients are pooled, or a high discontinuation rate that undermines the dose-selection rationale, could also leave the regulatory path ambiguous and require additional data before an NDA filing.